Cancer Research Tech. Ltd. v. Barr Laboratories, Inc., 10-1204

Patent infringement suit related to compounds and methods for treating cancer

Cancer Research Tech. Ltd. v. Barr Laboratories, Inc., 10-1204,  concerned a challenge to the district court's judgment finding the '291 patent unenforceable for prosecution laches and inequitable conduct, in a patent infringement suit related to a genus of tetrazine derivative compounds and methods for treating cancer by administering those compounds.

In reversing, the court held that the district court committed legal error in holding the '291 patent unenforceable for prosecution laches in the absence of any evidence of intervening rights.  The court also held that the district court's decision holding the '291 patent unenforceable for inequitable conduct is reversed as the district court committed clear error in finding that plaintiff acted with deceptive intent.

Related Link:

• Read the Federal Circuit's Full Decision in Cancer Research Tech. Ltd. v. Barr Laboratories, Inc., 10-1204